Literature DB >> 6252776

Primary hepatocelluar carcinoma in Saudi Arabia. A clinicopathological study of 54 cases.

M Atiyeh, M A Ali.   

Abstract

A high incidence of primary hepatocelluar carcinoma in the Orient and Africa has been reported. It is also seen frequently in Saudi Arabia. In a series of 54 consecutive patients diagnosed histologically, the male to female ratio was 10:1--the highest reported. The peak age was between 40-60 years and the mean survival was eight months. This is in contrast to hepatocelluar carcinoma in Africa where the age is between 25-35 years and the disease runs a quick downhill course simulating an abscess. Macronodular cirrhosis was diagnosed histologically or suggested clinically in 80% of the cases. Serum was positive for HBsAg in 55% of the patients, compared with 8% in healthy blood donors. These figures are as significant as reports from high incidence areas and point strongly to a possible causal relationship between HBV infection and the development of primary hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6252776

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  2 in total

Review 1.  Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines.

Authors:  Ayman A Abdo; Mazen Hassanain; AbdulRahman AlJumah; Ashwaq Al Olayan; Faisal M Sanai; Hamad A Alsuhaibani; Huda Abdulkareem; Khalid Abdallah; Mohammad AlMuaikeel; Mohammad Al Saghier; Mohammad Babatin; Monther Kabbani; Shouki Bazarbashi; Peter Metrakos; Jordi Bruix
Journal:  Ann Saudi Med       Date:  2012 Mar-Apr       Impact factor: 1.526

2.  Screening of pregnant Saudi women for hepatitis B surface antigen.

Authors:  Yagob Y Al-Mazrou; Mohamed Al-Jeffri; Mohamed K M Khalil; Yasser S Al-Ghamdi; Ameen Mishkhas; Mohamed Bakhsh; Mostafa Eisa; Mohamed Nageeb; Salah Tumsah
Journal:  Ann Saudi Med       Date:  2004 Jul-Aug       Impact factor: 1.526

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.